25 results on '"Huang D"'
Search Results
2. P2.09-33 A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
3. EP12.01-55 Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)
4. EP11.02-06 Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS
5. 224P Genetic landscape, PD-L1 expression, and CD8+ infiltration in Chinese pulmonary carcinoids
6. OA14.03 Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study.
7. EP08.01-070 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
8. EP08.01-014 Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
9. P4.11E.03 Safety and Efficacy of AL2846 Combined with TQB2450 In NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)
10. MA06.05 A Phase II Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-Treated with Crizotinib and Platinum-Based Chemotherapy
11. OA14.05 KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
12. OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
13. MA02.01 Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial
14. P19.01 RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
15. 60TiP ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)
16. P76.100 Primary Drug Resistance to EGFR-TKIs by EGFR p.V1010M Germline Mutation Combined with EGFR p.L858R Somatic Mutation and its Pedigree Analysis
17. P81.02 Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
18. P34.09 The Dynamic Changes of ctDNA and cfDNA in the Perioperative Period of Early NSCLC have the Potential to Predict the Risk of Recurrence
19. P2.01-78 A Meta-Analysis and Bioinformatics Exploration of the Prognostic Value of TP53 Co-Mutations in EGFR Mutated NSCLC
20. MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)
21. P104 Anti-PD-1 Combination Therapy in Second or Later Lines in Patients with Advanced Non Small Cell Lung Cancer
22. P013 Anti-PD-1 Combination Therapy as Second Line Treatment or Beyond in Patients with Advanced Non-Small Cell Lung Cancer
23. P3.01-074 Genomic Analysis of Tumor and Plasma in T790M Mutant Positive EGFR Lung Cancer Patients before and after Osimertinib Treatment
24. P2.03-043 A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
25. OA01.06 First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.